IBI362

DRUG19 trials

Sponsors

Innovent Biologics (Suzhou) Co. Ltd.

Conditions

Adolescents With ObesityAdolescents With Obesity or Overweight With Weight-Related ComorbiditiesHeart Failure With Mildly Reduced Ejection FractionHeart Failure With Preserved Ejection Fraction (HFPEF)HypertensiveMetabolic Dysfunction-associated Fatty Liver Disease (MAFLD)Metabolic Dysfunction-associated Steatohepatitis (MASH)Obese Subjects

Phase 1

Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IBI362 in Overweight or Obesity Subjects

CompletedNCT04440345

Innovent Biologics (Suzhou) Co. Ltd.Overweight or Obesity

Start: 2020-06-16End: 2021-08-06Updated: 2023-11-28

Multiple-dose Tolerability and Pharmacokinetic of IBI362 in Chinese Patients With T2DM

CompletedNCT04466904

Innovent Biologics (Suzhou) Co. Ltd.Type 2 Diabetes

Start: 2020-09-12End: 2021-05-28Updated: 2021-07-23

Pharmacokinetics of IBI362 in Subjects With and Without Renal Impairment

CompletedNCT05793450

Innovent Biologics (Suzhou) Co. Ltd.Renal Impairment

Start: 2023-05-05End: 2023-11-17Updated: 2024-02-20

A Study to Evaluate the Drug-drug Interactions (DDIs) of IBI362 With Metformin, Warfarin, Atorvastatin, Digoxin in Overweight or Obese Subjects

CompletedNCT05815680

Innovent Biologics (Suzhou) Co. Ltd.Obese Subjects, Overweight Subjects

Start: 2023-04-06End: 2023-10-30Updated: 2023-11-14

This is a Study to Evaluate the Pharmacokinetics and Safety of IBI362 in Chinese Adolescents With Obesity

CompletedNCT06536023

Innovent Biologics (Suzhou) Co. Ltd.Adolescents With Obesity

Start: 2024-08-30End: 2025-08-01Updated: 2025-09-12

Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg in Patients With Moderate to Severe Obesity

Active, not recruitingNCT07000955

Innovent Biologics (Suzhou) Co. Ltd.Obesity

Start: 2025-06-17End: 2027-05-14Updated: 2025-12-15

Phase 2

A Study of IBI362 Evaluating Weight Loss in Obese and Overweight Chinese Subjects

CompletedNCT04904913

Innovent Biologics (Suzhou) Co. Ltd.Overweight/ Obesity

Start: 2021-06-08End: 2023-12-06Updated: 2025-11-17

A Study of IBI362 in Chinese Patients With Type 2 Diabetes

CompletedNCT04965506

Innovent Biologics (Suzhou) Co. Ltd.Type 2 Diabetes

Start: 2021-09-06End: 2022-06-11Updated: 2023-12-27

A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With Obesity

RecruitingNCT06862908

Innovent Biologics (Suzhou) Co. Ltd.Heart Failure With Mildly Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction (HFPEF), Obesity

Start: 2025-04-01End: 2027-02-11Target: 141Updated: 2025-07-11

A Study of IBI362 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)

RecruitingNCT06937749

Innovent Biologics (Suzhou) Co. Ltd.Metabolic Dysfunction-associated Steatohepatitis (MASH)

Start: 2025-07-01End: 2027-07-22Target: 165Updated: 2025-11-20

Phase 3

A Study of IBI362 in Participants With Obesity or Overweight

CompletedNCT05607680

Innovent Biologics (Suzhou) Co. Ltd.Obesity Or Overweight

Start: 2022-11-14End: 2024-04-16Updated: 2024-11-12

A Study of IBI362 in Participants With Type 2 Diabetes

CompletedNCT05606913

Innovent Biologics (Suzhou) Co. Ltd.Type 2 Diabetes

Start: 2023-01-06End: 2024-04-09Updated: 2024-08-23

A Study of IBI362 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and Exercise

CompletedNCT05628311

Innovent Biologics (Suzhou) Co. Ltd.Type 2 Diabetes

Start: 2023-01-06End: 2024-05-09Updated: 2024-08-20

A Study of IBI362 9 mg in Chinese Adults With Obesity

Active, not recruitingNCT06164873

Innovent Biologics (Suzhou) Co. Ltd.Obesity

Start: 2023-12-27End: 2025-09-19Updated: 2024-08-27

A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and Obesity

CompletedNCT06184568

Innovent Biologics (Suzhou) Co. Ltd.Obesity, Type 2 Diabetes

Start: 2024-02-29End: 2026-02-09Updated: 2026-06-11

A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease （MAFLD）

Active, not recruitingNCT06884293

Innovent Biologics (Suzhou) Co. Ltd.Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD), Overweight

Start: 2025-05-09End: 2027-06-30Updated: 2026-05-12

A Study of IBI362 in Chinese Subjects With Obstructive Sleep Apnea and BMI≥28 kg/m2

RecruitingNCT06931028

Innovent Biologics (Suzhou) Co. Ltd.Obesity, Obstructive, Sleep Apnea

Start: 2025-06-12End: 2027-06-11Target: 260Updated: 2025-06-29

A Study of IBI362 in Chinese Adolescents With Obesity or Overweight

RecruitingNCT07255209

Innovent Biologics (Suzhou) Co. Ltd.Adolescents With Obesity or Overweight With Weight-Related Comorbidities

Start: 2025-12-29End: 2028-10-31Target: 180Updated: 2026-01-08

Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/Obesity

RecruitingNCT07469800

Innovent Biologics (Suzhou) Co. Ltd.Hypertensive, Obesity, Overweight

Start: 2026-04-23End: 2027-04-15Target: 336Updated: 2026-05-27

Related Papers

Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial.

2026-06-07

1226-OR: Mazdutide vs. Semaglutide in Chinese Adults with Type 2 Diabetes and Obesity (DREAMS-3): A Randomised, Open-Label, Phase 3b Trial

Diabetes2026-06-07

1225-OR: Efficacy and Safety of Mazdutide 9 mg in Chinese Adults with Obesity: Results from the Phase 3 GLORY-2 Trial

Diabetes2026-06-07

1133-OR: Safety, Tolerability, and Pharmacokinetics of Once-Weekly Mazdutide in Chinese Adolescents with Obesity: A Phase 1b Trial

Diabetes2026-06-05

Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight

New England Journal of Medicine2025-05-2543 citations

1856-LB: Efficacy and Safety of Mazdutide in Chinese Participants with Overweight or Obesity (GLORY-1)

Diabetes2024-06-149 citations

1866-LB: A Phase 2 Study of Mazdutide 9 mg in Chinese Adults with BMI of 30 kg/m2 or more

Diabetes2024-06-146 citations

1857-LB: Improvement of Liver Steatosis by Mazdutide in Chinese Participants with Overweight or Obesity—An Exploratory Analysis of GLORY-1

Diabetes2024-06-142 citations

A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity

Nature Communications2023-12-1479 citations

ODP014 Safety and Efficacy of IBI362 (LY3305677) 9 mg and 10 mg in Chinese Adults with Overweight or Obesity

Journal of the Endocrine Society2022-11-01

Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial.

2022-10-0753 citations

A phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes

Nature Communications2022-06-2444 citations

IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple ascending dose phase 1b study.

2021-08-1337 citations